ACH-CANDESARTAN TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

CANDESARTAN CILEXETIL

متاح من:

ACCORD HEALTHCARE INC

ATC رمز:

C09CA06

INN (الاسم الدولي):

CANDESARTAN

جرعة:

32MG

الشكل الصيدلاني:

TABLET

تركيب:

CANDESARTAN CILEXETIL 32MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

30/100

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

ملخص المنتج:

Active ingredient group (AIG) number: 0135220004; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2012-02-02

خصائص المنتج

Page 1 of 38
PRODUCT MONOGRAPH
ACH-CANDESARTAN
Candesartan Cilexetil
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AIMIPENEM AND CILASTATIN FOR INJECTION T
1
Receptor Blocker
Accord Healthcare Inc.
3535 boul. St. Charles suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
March 30, 2017
Submission Control Number: 203995
Page 2 of 38
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
..........................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOSAGE AND ADMINISTRATION
....................................................................................
17
OVERDOSAGE
.......................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 20
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 23
PART II: SCIENTIFIC INFORMATION
................................................................................
24
PHARMACEUTICAL INFORMATION
..............................................................................
24
CLINICAL TRIALS
.......................................................................